Melior Discovery will run preclinical in vivo pharmacology studies to support Linnaeus’ ARPA-H PROSPR-funded development of LNS8801 aimed at healthspan preservation. The announcement is a positive progress update for the program, but it is preclinical and likely limited in near-term pricing impact.
Melior Discovery will run preclinical in vivo pharmacology studies to support Linnaeus’ ARPA-H PROSPR-funded development of LNS8801 aimed at healthspan preservation. The announcement is a positive progress update for the program, but it is preclinical and likely limited in near-term pricing impact.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.15
